Cholangiocarcinoma | Nature Reviews Disease Primers
Cholangiocarcinoma With FGFR Genetic Aberrations: A Unique Clinical Phenotype | JCO Precision Oncology
Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma | British Journal of Cancer
FGFR2 genomic aberrations: Achilles heel in the management of advanced cholangiocarcinoma - Cancer Treatment Reviews
Incorporating FGFR Inhibitors into the Treatment Paradigm for Cholangiocarcinoma: Current Concepts and Future Directions - CCA News Online | CCA News Online
Cholangiocarcinoma With FGFR Genetic Aberrations: A Unique Clinical Phenotype | JCO Precision Oncology
IJMS | Free Full-Text | FGFR Fusions in Cancer: From Diagnostic Approaches to Therapeutic Intervention | HTML
Genomic alterations in cholangiocarcinoma: clinical significance and relevance to therapy
Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study - The Lancet Oncology
FGFR Inhibitors: Clinical Activity and Development in the Treatment of Cholangiocarcinoma | Request PDF
Clinical trials of FGF/FGFR signaling-targeted therapies for CCA. | Download Scientific Diagram
Cholangiocarcinoma With FGFR Genetic Aberrations: A Unique Clinical Phenotype | JCO Precision Oncology
Advances and challenges in targeting FGFR signalling in cancer | Nature Reviews Cancer
Frontiers | Emergence of Intrahepatic Cholangiocarcinoma: How High-Throughput Technologies Expedite the Solutions for a Rare Cancer Type | Genetics
Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study - The Lancet Oncology
Cells | Free Full-Text | Fibroblast Growth Factor Receptors (FGFRs) and Noncanonical Partners in Cancer Signaling | HTML
Targeted genomic profiling revealed a unique clinical phenotype in intrahepatic cholangiocarcinoma with fibroblast growth factor receptor rearrangement - ScienceDirect
Novel Therapies Targeting FGFR-Altered Advanced Cholangiocarcinoma
Frontiers | Fibroblast Growth Factor Receptor 1-4 Genetic Aberrations as Clinically Relevant Biomarkers in Squamous Cell Lung Cancer | Oncology
Cholangiocarcinoma With FGFR Genetic Aberrations: A Unique Clinical Phenotype | JCO Precision Oncology
Novel Therapies Targeting FGFR-Altered Advanced Cholangiocarcinoma
Molecular targeted therapies: Ready for “prime time” in biliary tract cancer - Journal of Hepatology
Cholangiocarcinoma With FGFR Genetic Aberrations: A Unique Clinical Phenotype | JCO Precision Oncology
Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma | British Journal of Cancer
Figure 2 from Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma | Semantic Scholar
Schematic representation of commonly found FGFR2 fusion proteins in... | Download Scientific Diagram
Frontiers | Fibroblast Growth Factor Receptor 1-4 Genetic Aberrations as Clinically Relevant Biomarkers in Squamous Cell Lung Cancer | Oncology
